Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Solid Tumor
Urothelial Carcinoma
Solid Tumor, Adult
Bladder Cancer
Non-muscle-invasive Bladder Cancer
FGFR3 Gene Mutation
FGFR3 Gene Alteration
Advanced Solid Tumor
Advanced Urothelial Carcinoma
Urinary Tract Cancer
Urinary Tract Tumor
Urinary Tract Carcinoma

Interventions

DRUG: TYRA-300

Sponsor

Tyra Biosciences, Inc